GLP-1 muscle loss shows up in trials as a drop in lean mass, but semaglutide and tirzepatide lower body weight with more fat lost than lean mass.1,2,3 Lean mass includes muscle and other body tissues that are not fat.
About 75% of the weight lost by week 72 was fat mass and 25% lean mass in a body-scan substudy of the tirzepatide trial SURMOUNT-1.4 People given a placebo instead lost much less weight, but in the same split.4
A review cautions that a drop in lean mass is not the same as a loss of skeletal muscle: lean mass also includes body water, organs and connective tissue.5
Glucagon-like peptide 1 (GLP-1) medications are used to treat type 2 diabetes, and some are used for weight loss in people with obesity.6
Every Telezen MD GLP-1 plan includes compounded GLP-1 medication. Compounding is generally a practice in which a licensed pharmacist or physician combines, mixes or alters the ingredients of a drug to create a medication tailored to one patient.
Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA).7 The trial results in this article describe the products studied, not a compounded version. Whether a compounded medicine suits you, and how it compares with those products, is a question for the physician consultation every plan includes.
GLP-1 Muscle Loss: How Much of the Weight You Lose Is Lean Mass?
Lean mass made up from about a quarter to nearly two fifths of the weight lost on these medicines in trials and reviews, so most of the weight lost was fat.4,8,1 A median 28.3% of the weight lost on these medicines was attributed to losses in muscle-related measures, in a review of 35 primary studies of semaglutide, tirzepatide, liraglutide or dulaglutide in adults that lasted a median 26 weeks.9 In the middle half of the groups in those studies, that share ran from 15.9% to 39.9%, and muscle-related losses varied widely between studies, 42.9% of which were at low risk of bias.9
- SURMOUNT-1, in adults with obesity or overweight, each measure’s own change from the start of the trial, not a share of the weight lost: by week 72, body weight changed by -21.3%, fat mass by -33.9% and lean mass by -10.9% with tirzepatide, against -5.3%, -8.2% and -2.6% with a placebo.4
- A review of twenty-two randomized trials of GLP-1 medications included 2258 participants.8 That review found mean differences of -3.55 kg in body weight and -0.86 kg in lean mass, with lean mass making up about 25% of the weight lost.8
- A review of seven studies with 821 patients taking GLP-1 medications at obesity doses found that, compared with a placebo, lean mass changed by -1.74 kg, though results varied widely between the studies.10
- A retrospective study at one commercial wellness studio reported that 94 people in its weight management programme receiving once-weekly compounded semaglutide/cyanocobalamin injections lost an average 4.57% of their body weight after 3 months.11 They lost fat mass while also losing small amounts of lean mass and skeletal muscle mass, the study reported.11
These are group results; they should not be read as a forecast of any one person’s result.
Is Lean Mass Loss Worse on a GLP-1 Medication Than With Diet and Exercise?
Not clearly worse: in one review of twenty randomized trials, lean mass made up a broadly similar share of the weight lost on these medicines and with intensive lifestyle programs.1 A review of 35 studies, 42.9% of them at low risk of bias, found muscle-related losses passed limits set in advance more often with the medicines.9
- A review of twenty randomized trials compared these medicines with intensive lifestyle programs in adults with overweight or obesity.1 In the review, lean mass made up 26.2% of the weight lost with lifestyle programs, against 25.4% with tirzepatide and 35.2% with semaglutide.1 Its authors conclude that lean mass loss during significant weight loss is substantial, and that its share is broadly comparable between these medicines and lifestyle programs.1
- A review of 35 studies compared muscle-related losses with limits set in advance.9 In that review, muscle-related losses went beyond those limits in about two thirds of the groups on these medicines and in nearly half of the non-drug groups that lost weight.9 The studies in that review lasted a median of 26 weeks, with a median of 78 participants, and 42.9% were at low risk of bias.9
Does Losing Lean Mass Affect Your Strength and Daily Life?
It is not yet known whether the lean mass lost on these medicines makes people meaningfully weaker or less able to manage everyday physical tasks.12 None of the 35 studies in one review reported an objective measure of physical function.9
Muscle supports strength, balance and physical function, and it takes energy to maintain itself.13,14 Sarcopenia is the gradual loss of muscle mass and strength that can occur with aging, especially in people who are less physically active.
The SEMALEAN study, a prospective study that enrolled 115 patients with obesity taking semaglutide, reported handgrip strength 4.5 kg higher at 12 months than at the start.15
A meta-analysis of ten studies with 660 people taking semaglutide found no significant pooled change in handgrip strength.16 Its authors call the evidence insufficient to tell whether semaglutide changes handgrip strength, with very low certainty.16 The analysis pooled changes within treated groups rather than comparisons with a control group, so its results do not establish that strength is preserved.16
In a randomized trial of 193 adults with obesity who had first lost weight on a low-calorie diet, absolute strength was preserved on the GLP-1 medicine liraglutide.17 Strength relative to body weight rose 1.0% with liraglutide and fell 7.8% with a placebo.17 In a secondary analysis of that trial, exercise, alone or with liraglutide, improved stair-climb time and peak oxygen consumption compared with liraglutide alone, which did not improve physical fitness.17
Is Muscle Loss on Tirzepatide Different From Muscle Loss on Semaglutide?
Not clearly: the comparisons come from separate trials, not a head-to-head trial, so they do not show that either medicine is better for keeping muscle. In one review’s pooled trials, lean mass made up a smaller share of the weight lost with tirzepatide than with semaglutide, while another ranked tirzepatide 15 mg and semaglutide 2.4 mg weekly the most effective for weight and fat loss but among the least effective at preserving lean mass.1,8
The tirzepatide label describes it as acting on two receptors: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 receptor.3
The share figures come from a review of twenty randomized trials: lean mass was 25.4% of the weight lost with tirzepatide, against 35.2% with semaglutide.1 The ranking comes from a review of twenty-two randomized trials.8
Do Age and Sex Change How Much Lean Mass You Lose?
In post hoc analyses of the body-scan substudy of a tirzepatide trial, the share of weight lost as lean mass stayed consistent across most subgroups by sex, age and amount of weight lost.4 A narrative review of the evidence in older adults found too little research to tell whether they are more vulnerable to muscle loss on these medicines, or to the frailty that could follow.18
The tirzepatide results came from analyses made after the trial, of the 160 people, of 2539 in SURMOUNT-1, who had dual-energy X-ray absorptiometry (DXA) body scans, and the oldest age group was aged 65 years or older.4
In a post hoc analysis of the SURMOUNT and SUMMIT trials of tirzepatide, adults aged 65 years or older had clinically meaningful weight reduction, broadly comparable to younger adults.19 The same post hoc analysis found no clinically meaningful difference from placebo in their rates of falls or fractures.19
In a review of 35 studies, average participant ages ranged from 20 to 63.7 years.9 In older adults with type 2 diabetes, studies that followed people over time or looked back at their records found lower handgrip strength and faster sarcopenia with prolonged semaglutide use, a review of muscle strength in older adults reports.20
A position statement from the European Association for the Study of Obesity says obesity care in older adults should focus on preserving muscle mass, functional capacity and quality of life, not weight loss alone.21 It recommends moderate calorie restriction with adequate protein, structured exercise that combines several types, and behavioral support, with obesity medicines or surgery where appropriate.21
What Happens When You Stay On or Stop a GLP-1 Medication?
Stopping brought weight back in trials: one year after semaglutide and the lifestyle intervention were withdrawn in a randomized trial’s extension, participants had regained two-thirds of the weight they had lost.22,23 In SURMOUNT-4, a randomized trial in people with obesity or overweight, withdrawing tirzepatide led to substantial regain, while continued treatment maintained and added to the weight lost.23 A joint expert guidance statement on treating U.S. adults with obesity medicines gives continuing them during weight maintenance a strong recommendation.24
In the prospective SEMALEAN study of 115 patients with obesity taking semaglutide, lean mass first declined, a change of -3 kg at 7 months, and then stabilized.15
A randomized placebo-controlled trial of supervised exercise, the once-daily GLP-1 medicine liraglutide, or both, followed 109 adults with obesity for one year after treatment ended.25 In that trial’s one-year follow-up, all four groups (supervised exercise, liraglutide, both, or placebo) had similar increases in lean mass.25,17 One year after stopping, the liraglutide groups had a fat percentage similar to the placebo groups’.25
The trial reported that those who had taken liraglutide alone regained 9.6 kg in that year, while body weight and body composition held after supervised exercise ended.25
A review of weight regain after these medicines says structured exercise may help reduce regain and preserve lean mass, while evidence for dietary, behavioral, tapering or other drug strategies remains limited.26
Plan any stop with your provider, and for more, see weight regain after stopping a GLP-1.
How to Protect Muscle on a GLP-1 Medication
Muscle mass can be significantly preserved during weight loss by building resistance training, adequate protein and body-composition monitoring into treatment, the authors of a review of twenty randomized trials conclude.1 In that review, weight lost through lifestyle programs with resistance training was 17.5% lean mass, the most favorable share it reported.1
How Much Protein Do You Need on a GLP-1 Medication?
A review of medical nutrition in the GLP-1 era proposes, rather than tests, at least 1.2 g of protein per kilogram of body weight a day, though protein needs on a GLP-1 medication are not settled.27,28 It allows up to 1.6 g/kg for appropriate adults without chronic kidney disease.28 A review of trials of these medicines with diet guidance says further trials are needed to clarify protein needs.27
- Mayo Clinic Press quotes a clinician who commonly uses a target of 1.5 g/kg a day for GLP-1 patients, individualized and based on ideal body weight, not actual body weight.29 It also says most healthy adults benefit from 20 to 30 grams of protein per meal, spread through the day, though needs differ with age, activity and health.13
The two studies below tested diets, not these medicines:
- An analysis of 87 studies of reduced-calorie diets in adults: protein intakes above 1.05 g/kg were linked with 0.60 kg more fat-free mass (the body’s tissue other than fat) kept than lower intakes.30 In studies lasting more than 12 weeks, the difference was 1.21 kg.30
- A review of randomized trials in adults without chronic kidney disease: compared with normal- or low-protein diets, high-protein diets lowered body fat but did not significantly change fat-free mass.31 In 19 of its trials, they did not significantly change serum creatinine, a blood test used to estimate kidney function.31 Because most of its studies were short, the long-term effects on the kidneys remain uncertain.31
The National Institutes of Health says some people with chronic kidney disease may need to eat moderate amounts of protein so waste does not build up in the blood.32 If you have kidney disease, ask before you raise your protein.
Until trials settle it, take the review’s proposed minimum of 1.2 g/kg a day to your provider as a starting point, and set a daily target together that fits your kidneys and other health conditions.28 For what to eat, see the GLP-1 diet plan.
Does Resistance Training Protect Muscle During Weight Loss?
Exercise added to calorie-restricted diets kept more lean mass in people with overweight or obesity, and strength training kept more than calorie restriction alone, in one review of trials.33 The Centers for Disease Control and Prevention (CDC) says adults need at least 2 days of muscle-strengthening activity each week.34
- A review of 34 randomized trials with 1455 participants with overweight or obesity found that adding exercise to calorie restriction prevented nearly half of the loss of fat-free mass, 45.7% on average.33 In that review, the effect of endurance training fell just short of statistical significance.33 Only two of its studies reported skeletal muscle mass, and both pointed to exercise preserving muscle.33
- A review of 18 randomized trials with 5,620 adults with overweight or obesity compared exercise plus weight-loss medicines with the medicines alone.35 So for people already taking these medicines, adding exercise in that review lowered weight and body mass index further, but brought no significant improvement in lean body mass.35
Does Creatine Help?
In postmenopausal women, creatine taken with resistance training brought small but meaningful gains in lean mass and strength, without evidence of harm.36 Creatine is an amino acid produced by the body and a popular dietary supplement.
The review behind this pooled seven trials with 608 randomized participants whose mean age was about 62, in trials lasting 12 to 104 weeks.36 These small but meaningful gains in lean mass and strength were seen mainly at 5 g a day or more, taken with resistance training.36 The review studied postmenopausal women, so its results should not be read as applying to everyone on a GLP-1 medication; ask your provider before taking creatine.
How Can You Tell Whether You Are Losing Muscle?
Tests that providers may use to measure body composition include magnetic resonance imaging (MRI), a bone density test known as a dual-energy X-ray absorptiometry (DXA) scan, and bioelectrical impedance. Bioelectrical impedance measures how differently muscle and fat tissue conduct electricity.
Muscle and strength loss that starts to interfere with daily activities such as walking, standing up or carrying groceries may be a sign of sarcopenia.37
A study at a French hospital compared 3 commercially available smart scales with DXA in 48 to 53 patients per scale.38 Its authors found the scales were not accurate for body composition and say they should not replace DXA in patient care.38
A January 2020 clinical guideline from the American Society for Parenteral and Enteral Nutrition, based on a limited number of studies and expert opinion, recommends DXA for measuring fat mass in patients with a variety of disease states.39 For lean mass, the guideline says DXA’s validity remains unknown in any clinical population.39 It said no recommendation could be made at that time for bioelectrical impedance in clinical care, because data supporting its validity in any specific patient population were limited by each manufacturer’s proprietary models.39
Ask your provider which test they would use, and whether to repeat it during treatment.
Are Semaglutide and Tirzepatide Approved to Prevent Muscle Loss?
No: preventing muscle loss is not among the uses listed on the labels of Zepbound (tirzepatide) and Wegovy (semaglutide) injections.3,2
With a reduced-calorie diet and more physical activity, the tirzepatide label approves tirzepatide for losing excess weight and keeping it off long term in adults with obesity, or with overweight and a weight-related condition.3 The semaglutide injection label approves the same use, and also in children aged 12 years and older with obesity.2
Compounded drugs, including compounded semaglutide and tirzepatide, are not approved by the FDA, which does not verify their safety, effectiveness or quality before they are marketed.7 The FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an approved drug, and that one might be appropriate when the approved drug is not commercially available.40
What a Telezen MD GLP-1 Plan Includes
Every Telezen MD GLP-1 plan includes a physician consultation, provider monitoring, compounded GLP-1 medication and free, expedited shipping. Bring the questions at the end of this article to that physician consultation.
At no extra cost, every plan also includes The GLP-1 Nutrition Protocol™, a proprietary program, available only to Telezen MD patients, that teaches how to eat on a GLP-1 medication. It has 7 modules and 26 lessons, and Telezen MD describes one of its modules as covering protein and muscle preservation.
GLP-1 patients can call or text a concierge support team of real people at any time.
Every plan also includes Lose It for Life™, a self-paced digital course, with lifetime access, on changing the beliefs behind emotional eating, body-image struggles and old habits. It is an educational practice, not medical treatment or psychotherapy.
Risks, Side Effects and Who Should Avoid a GLP-1 Medication
GLP-1 medications consistently increased stomach and gut side effects in trials, and their labels rule them out for some people.27,3,2 These side effects included nausea, diarrhea, constipation and vomiting, often depending on the dose, and the semaglutide label says they are sometimes severe.27,2
Losing weight quickly while eating too little protein and too few nutrients can add to muscle loss, clinicians at Cleveland Clinic and Mayo Clinic say.41,29
The tirzepatide label notes reports of acute kidney injury in people taking GLP-1 medications, in some cases needing dialysis, mostly after nausea, vomiting or diarrhea that led to dehydration.3 MedlinePlus advises telling your provider if you have recently had diarrhea, nausea or vomiting, or cannot drink liquids by mouth.42
The tirzepatide and semaglutide labels also warn of inflammation of the pancreas (pancreatitis), whose signs may include persistent or severe stomach pain, sometimes spreading to the back.3,2 If pancreatitis is suspected, both labels say to stop the medicine promptly and contact your provider.3,2 Both labels also link the medicines with more gallbladder disease, including gallstones on the semaglutide label, and say to contact your provider if it is suspected.3,2
Tell your provider before starting if any of these apply to you:
- Certain thyroid tumors: the tirzepatide and semaglutide labels rule the medicines out for anyone with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2.3,2
- A past or present eating disorder: a review of emerging concerns and early evidence warns that the effects that reduce appetite and food preoccupation may also reinforce restriction and relapse in vulnerable people.43 Its authors propose routine eating disorder screening before and during treatment.43
- Older age: an editorial reported by the Endocrine Society calls for assessing muscle mass, physical function and nutrition before these medicines are prescribed to older patients.44
- Severe gastroparesis: the semaglutide label says the medicine is not recommended for people with this condition.2
- Insulin or a sulfonylurea: the semaglutide label says the risk of low blood sugar is higher when it is used with these diabetes medicines.2 It advises considering a lower dose of them when starting semaglutide.2
- Pregnancy: the tirzepatide and semaglutide labels say the medicine may harm an unborn baby and should be stopped once pregnancy is recognized.3,2 Tell your provider if you are pregnant or breastfeeding.42
- Children and teenagers: the tirzepatide label says its safety and effectiveness have not been established in children.3
Why Weight Lost on a GLP-1 Medication Includes Lean Mass
Lean mass loss on these medicines appears to be largely related to the weight loss itself, although the certainty of this evidence is low.12 That was the finding of a review of 60 research articles, 46 of them randomized trials.12
Calorie restriction on its own reduces both fat mass and fat-free mass, particularly skeletal muscle.33 Another review proposes that much of the drop in lean mass is the body adapting to carrying less load after marked weight loss.45
What to Keep in Mind About the Research
Studies of lean mass on these medicines measured and reported body composition in such different ways that one review could not pool them.9
- Study quality: in a review of 35 studies, 42.9% of the studies were at low risk of bias, and 10 set body composition as a main outcome in advance.9
- Consistency: in a review of twenty randomized trials, results varied moderately between trials, and no publication bias was detected.1
Questions to Ask Your Provider
- Could I be losing muscle as well as fat, and how would we measure it?
- How much protein should I aim for, given my kidneys and my other health conditions?
- What kind of resistance training is safe for me to start, and how often?
- Does my age or my current strength change how we should approach weight loss?
- If I decide to stop, how would we plan it?
- Why would a compounded medicine suit me, and how does it compare with the products studied in trials?
Muscle, protein and whether a GLP-1 medication fits you are questions for the physician consultation every Telezen MD GLP-1 plan includes: see how to get started.
Frequently Asked Questions
Do you lose muscle on a GLP-1 medication?
Some: in trials of semaglutide and tirzepatide, people lost some lean mass along with fat, though they lost more fat than lean mass. Lean mass includes muscle and other body tissues that are not fat.
How do you prevent muscle loss on a GLP-1 medication?
Muscle mass can be significantly preserved during weight loss by building resistance training, adequate protein and body-composition monitoring into treatment, a review of twenty randomized trials concludes. Protein needs on a GLP-1 medication itself are not yet settled.
Is muscle loss on tirzepatide different from muscle loss on semaglutide?
Not clearly: in one review’s pooled trials, lean mass made up a smaller share of the weight lost with tirzepatide than with semaglutide, while another review ranked both, at the weekly doses it studied, the most effective for weight and fat loss but among the least effective at preserving lean mass.
Are semaglutide and tirzepatide approved to prevent muscle loss?
No: preventing muscle loss is not among the uses listed on the labels of Zepbound (tirzepatide) and Wegovy (semaglutide) injections.
Sources
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/41877354/
- WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use: highlights of prescribing information, www.accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
- ZEPBOUND (tirzepatide) injection, for subcutaneous use: highlights of prescribing information, www.accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight., Diabetes, obesity & metabolism, 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/
- Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42839755/
- GLP-1 agonists: MedlinePlus Medical Encyclopedia, medlineplus.gov. https://medlineplus.gov/ency/article/007853.htm
- Compounding and the FDA: Questions and Answers | FDA, www.fda.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis., Metabolism: clinical and experimental, 2025. https://pubmed.ncbi.nlm.nih.gov/39719170/
- Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review., Annals of internal medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/41996180/
- Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs)., International journal of obesity (2005), 2026. https://pubmed.ncbi.nlm.nih.gov/42321502/
- Weight loss and body composition after compounded semaglutide treatment in a real world setting., Diabetes, obesity & metabolism, 2025. https://pubmed.ncbi.nlm.nih.gov/39776038/
- GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis., Drugs, 2026. https://pubmed.ncbi.nlm.nih.gov/42730869/
- Eating well on GLP-1 medications: Smaller appetites need quality nutrition – Mayo Clinic Press, mcpress.mayoclinic.org. https://mcpress.mayoclinic.org/healthy-eating/eating-well-on-glp-1-medications-smaller-appetites-need-quality-nutrition
- The Difference Between Muscle vs. Fat Weight, health.clevelandclinic.org. https://health.clevelandclinic.org/muscle-vs-fat-weight
- Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/41068996/
- Changes in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta-Analysis of Handgrip Strength., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42897109/
- Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity., Sports medicine (Auckland, N.Z.), 2026. https://pubmed.ncbi.nlm.nih.gov/41579235/
- GLP-1 receptor agonist therapy and skeletal muscle: A narrative review synthesizing adult evidence with implications for older adults., JAR life, 2026. https://pubmed.ncbi.nlm.nih.gov/42633386/
- Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42303274/
- Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions., British journal of pharmacology, 2026. https://pubmed.ncbi.nlm.nih.gov/41577337/
- European Association for the Study of Obesity Position Statement on the Diagnosis and Management of Obesity in Older Adults., Obesity facts, 2026. https://pubmed.ncbi.nlm.nih.gov/41308062/
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension., Diabetes, obesity & metabolism, 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial., JAMA, 2024. https://pubmed.ncbi.nlm.nih.gov/38078870/
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach., Obesity (Silver Spring, Md.), 2026. https://pubmed.ncbi.nlm.nih.gov/41782434/
- Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial., EClinicalMedicine, 2024. https://pubmed.ncbi.nlm.nih.gov/38544798/
- Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review., Metabolites, 2026. https://pubmed.ncbi.nlm.nih.gov/42941232/
- Dietary Strategies and Nutritional Management in Patients Receiving GLP-1 and Dual GIP/GLP-1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42037117/
- Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation., Clinical nutrition ESPEN, 2026. https://pubmed.ncbi.nlm.nih.gov/42036071/
- GLP-1 Nutrition: What to Eat – Mayo Clinic Press, mcpress.mayoclinic.org. https://mcpress.mayoclinic.org/nutrition-fitness/glp-1-nutrition-what-to-eat
- Effects of variation in protein and carbohydrate intake on body mass and composition during energy restriction: a meta-regression 1., The American journal of clinical nutrition, 2006. https://pubmed.ncbi.nlm.nih.gov/16469983/
- Effects of High-Protein Diets on Renal Function and Body Composition in Adults Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomised Trials., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42289790/
- Healthy Eating for Adults with Chronic Kidney Disease – NIDDK, www.niddk.nih.gov. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/healthy-eating-adults-chronic-kidney-disease
- Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat-Free and Skeletal Muscle Mass in Overweight or Obese Individuals-A Systematic Review With Pairwise Meta-Analysis and Network Meta-Analysis of Randomized Controlled Studies., Diabetes, obesity & metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/42144246/
- Adult Activity: An Overview | Physical Activity Basics | CDC, Centers for Disease Control and Prevention. https://www.cdc.gov/physical-activity-basics/guidelines/adults.html
- The Effects of Exercise Combined with Pharmacotherapy on Body Composition and Metabolic Parameters in Overweight/Obese Adults: A Meta-Analysis and Network Pharmacology Study., Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. https://pubmed.ncbi.nlm.nih.gov/42094035/
- Creatine monohydrate for lean mass, strength, and bone density in postmenopausal women: a systematic review and meta-analysis., Journal of the International Society of Sports Nutrition, 2026. https://pubmed.ncbi.nlm.nih.gov/42141930/
- Sarcopenia | Office on Women’s Health, womenshealth.gov, 2026. https://womenshealth.gov/sarcopenia
- Accuracy of Smart Scales on Weight and Body Composition: Observational Study., JMIR mHealth and uHealth, 2021. https://pubmed.ncbi.nlm.nih.gov/33929337/
- American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations., JPEN. Journal of parenteral and enteral nutrition, 2020. https://pubmed.ncbi.nlm.nih.gov/31216070/
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA, www.fda.gov. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Ozempic and Muscle Loss: What To Know, health.clevelandclinic.org. https://health.clevelandclinic.org/ozempic-muscle-loss
- Semaglutide Injection: MedlinePlus Drug Information, medlineplus.gov. https://medlineplus.gov/druginfo/meds/a618008.html
- Eating Disorders in the GLP-1 Era: A Spotlight on Emerging Clinical Risks, Research Gaps, and Practice Priorities., The International journal of eating disorders, 2026. https://pubmed.ncbi.nlm.nih.gov/42223191/
- GLP-1 Agonists and Muscle Loss: A Hidden Risk for Older Adults – Endocrine News, Endocrine Society, 2025. https://endocrinenews.endocrine.org/glp-1-agonists-and-muscle-loss-a-hidden-risk-for-older-adults
- Lean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance., High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2026. https://pubmed.ncbi.nlm.nih.gov/42701941/
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. Compounded medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.

